메뉴 건너뛰기




Volumn 6, Issue 1, 2009, Pages 21-24

The clinical impact of identifying metabolic syndrome in patients with diabetes: A cross-sectional study

Author keywords

Cardiovascular disease; Diabetes; Metabolic syndrome; Primary prevention; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

EID: 59149093320     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2009.004     Document Type: Article
Times cited : (4)

References (25)
  • 1
    • 0000241199 scopus 로고
    • Role of insulin resistance in human disease
    • Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1596-607.
    • (1988) Diabetes , vol.37 , pp. 1596-1607
    • Reaven, G.M.1
  • 2
    • 0042665536 scopus 로고    scopus 로고
    • Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study
    • Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.
    • (2003) Circulation , vol.108 , pp. 414-419
    • Sattar, N.1    Gaw, A.2    Scherbakova, O.3
  • 3
    • 0037116641 scopus 로고    scopus 로고
    • Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey
    • Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
    • (2002) JAMA , vol.287 , pp. 356-359
    • Ford, E.S.1    Giles, W.H.2    Dietz, W.H.3
  • 4
    • 0034837376 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality associated with the metabolic syndrome
    • Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-9.
    • (2001) Diabetes Care , vol.24 , pp. 683-689
    • Isomaa, B.1    Almgren, P.2    Tuomi, T.3
  • 5
    • 1842666845 scopus 로고    scopus 로고
    • The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the National Health and Nutrition Examination Survey II Mortality Study
    • Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173:309-14.
    • (2004) Atherosclerosis , vol.173 , pp. 309-314
    • Ford, E.S.1
  • 6
    • 0035897696 scopus 로고    scopus 로고
    • Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III)
    • Executive summary of the third report of the National Cholesterol Education Programme NCEP
    • Executive summary of the third report of the National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 7
    • 33644810298 scopus 로고    scopus 로고
    • JBS-2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(suppl v):v1-v52.
    • JBS-2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(suppl v):v1-v52.
  • 8
    • 79956344097 scopus 로고    scopus 로고
    • Statins for the prevention of cardiovascular events
    • The National Institute for Health and Clinical Excellence NICE, January
    • The National Institute for Health and Clinical Excellence (NICE). Statins for the prevention of cardiovascular events. Technology Appraisal 94. January 2006 www.nice.org.uk/page.aspx?o=TA094guidance
    • (2006) Technology Appraisal , vol.94
  • 9
    • 33748303084 scopus 로고    scopus 로고
    • Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study
    • Deedwania P, Barter P, Carmena R et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-28.
    • (2006) Lancet , vol.368 , pp. 919-928
    • Deedwania, P.1    Barter, P.2    Carmena, R.3
  • 10
    • 24144484876 scopus 로고    scopus 로고
    • The metabolic syndrome: Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
    • Kahn R, Buse, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes 2005;28:2289-304.
    • (2005) Diabetes , vol.28 , pp. 2289-2304
    • Kahn, R.1    Buse2    Ferrannini, E.3    Stern, M.4
  • 11
    • 44649131269 scopus 로고    scopus 로고
    • Metabolic syndrome - what is the clinical usefulness?
    • Kahn R. Metabolic syndrome - what is the clinical usefulness? Lancet 2008;371:1892-3.
    • (2008) Lancet , vol.371 , pp. 1892-1893
    • Kahn, R.1
  • 12
    • 46549089247 scopus 로고    scopus 로고
    • Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies
    • Sattar N, McConnachie A, Shaper AG et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008;371:1927-35.
    • (2008) Lancet , vol.371 , pp. 1927-1935
    • Sattar, N.1    McConnachie, A.2    Shaper, A.G.3
  • 13
    • 4644245424 scopus 로고    scopus 로고
    • Linking physicians' pay to the quality of care: A major experiment in the United Kingdom
    • Roland MO. Linking physicians' pay to the quality of care: a major experiment in the United Kingdom. N Engl J Med 2004; 351:1448-54.
    • (2004) N Engl J Med , vol.351 , pp. 1448-1454
    • Roland, M.O.1
  • 14
    • 34247487800 scopus 로고    scopus 로고
    • Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research
    • Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401.
    • (2007) Pharmacoepidemiol Drug Saf , vol.16 , pp. 393-401
    • Lewis, J.D.1    Schinnar, R.2    Bilker, W.B.3    Wang, X.4    Strom, B.L.5
  • 15
    • 33645978121 scopus 로고    scopus 로고
    • Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation
    • Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
    • (2006) Diabet Med , vol.23 , pp. 469-480
    • Alberti, K.G.1    Zimmet, P.2    Shaw, J.3
  • 16
    • 0029015738 scopus 로고
    • Waist circumference as a measure for indicating need for weight management
    • Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995;311:158-61.
    • (1995) BMJ , vol.311 , pp. 158-161
    • Lean, M.E.1    Han, T.S.2    Morrison, C.E.3
  • 17
    • 4043160640 scopus 로고    scopus 로고
    • Cardiovascular disease with diabetes or the metabolic syndrome: Should statins or fibrates be first line lipid therapy?
    • Robins SJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Current Opin Lipidol 2003;14:575-83.
    • (2003) Current Opin Lipidol , vol.14 , pp. 575-583
    • Robins, S.J.1
  • 18
    • 33746431474 scopus 로고    scopus 로고
    • Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)
    • Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85.
    • (2006) Diabetes Care , vol.29 , pp. 1478-1485
    • Knopp, R.H.1    d'Emden, M.2    Smilde, J.G.3    Pocock, S.J.4
  • 19
    • 7444269499 scopus 로고    scopus 로고
    • Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?
    • Stern MP, Williams K, Gonzalez-Villapando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-81.
    • (2004) Diabetes Care , vol.27 , pp. 2676-2681
    • Stern, M.P.1    Williams, K.2    Gonzalez-Villapando, C.3    Hunt, K.J.4    Haffner, S.M.5
  • 20
    • 33645969319 scopus 로고    scopus 로고
    • Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: Prospective, population based cohort study
    • Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006;332:878-82.
    • (2006) BMJ , vol.332 , pp. 878-882
    • Sundstrom, J.1    Riserus, U.2    Byberg, L.3    Zethelius, B.4    Lithell, H.5    Lind, L.6
  • 21
    • 31444432608 scopus 로고    scopus 로고
    • Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes
    • Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006;49:49-55.
    • (2006) Diabetologia , vol.49 , pp. 49-55
    • Guzder, R.N.1    Gatling, W.2    Mullee, M.A.3    Byrne, C.D.4
  • 22
    • 33748288389 scopus 로고    scopus 로고
    • Does the metabolic syndrome help select patients requiring high statin dose?
    • Scheen AJ. Does the metabolic syndrome help select patients requiring high statin dose? Lancet 2006;368:893-4.
    • (2006) Lancet , vol.368 , pp. 893-894
    • Scheen, A.J.1
  • 23
    • 33846365989 scopus 로고    scopus 로고
    • Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies
    • Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-14.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 403-414
    • Gami, A.S.1    Witt, B.J.2    Howard, D.E.3
  • 24
    • 1542374595 scopus 로고    scopus 로고
    • Coronary heart disease risk assessment in diabetes mellitus: Comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications
    • Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 2004; 21:238-45.
    • (2004) Diabet Med , vol.21 , pp. 238-245
    • Song, S.H.1    Brown, P.M.2
  • 25
    • 17844366883 scopus 로고    scopus 로고
    • Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: Results from a United Kingdom study
    • Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med 2005; 22:554-62.
    • (2005) Diabet Med , vol.22 , pp. 554-562
    • Guzder, R.N.1    Gatling, W.2    Mullee, M.A.3    Mehta, R.L.4    Byrne, C.D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.